| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Wells Fargo analyst Yanan Zhu maintains uniQure (NASDAQ:QURE) with a Overweight and lowers the price target from $80 to $60.
Chardan Capital analyst Daniil Gataulin maintains uniQure (NASDAQ:QURE) with a Buy and maintains $53 price target.
Leerink Partners analyst Joseph Schwartz maintains uniQure (NASDAQ:QURE) with a Outperform and lowers the price target from ...
uniQure (NASDAQ:QURE) reported quarterly losses of $(1.38) per share which missed the analyst consensus estimate of $(0.90) by ...
Biohaven stock plunged after the FDA rejected Vyglxia for spinocerebellar ataxia, prompting major R&D cuts and a William Bl...